Valvopathy was shown not to occur in excess with treatment and lorcaserin was generally well tolerated, with a low incidence of side effects such as headache, dizziness, fatigue, nausea
For context, this same principle applies to other peptide medications
this is particularly relevant for shorter follow-up trials (e.g
Parallel aliquots of the same WCL samples (30 g) were loaded as input controls and probed for total TFR1, GPX4, SLC7A11, and -actin
Yet there is currently only one FDA-approved adjunctive therapy for type 1: Symlin (pramlintide), a drug that is rarely used due to its long list of side effects
Additionally, it may be of limited clinical benefit in the ASD population based on behavioral limitations to adhere with continuous treatment